ZIOP - Earnings call transcript Q4 2019 | Alaunos Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Ziopharm Oncology Fourth Quarter and Year-End 2019 Conference Call. At this time, all participants are in a listen only mode [Operator Instructions]. Please be advised that today’s conference is being recorded [Operator Instructions].

I would now like to hand the conference over to your speaker today, Mr. of President Vice Taylor, Investor Relations. Chris you. Thank go Please ahead.

Chris Taylor

we welcome you, of Web to Oncology Ziopharm year-end Good results This review our of site, and And in operator. afternoon. to the afternoon, XXXX. ziopharm.com. conference of are for release, fourth the our XXXX our the XX-K issued Thank results quarter filed which call available both and webcast section Investor's

today's PowerPoint commentary. also included slides in webcast slides For to found purposes, of accompany Section. be site we have also informational Web in These Investor's a can our our set on the

this During potential forward-looking therapeutic will and regulatory a the statements, our in number information development pipeline, call, of company the candidates status, regarding including trends. statements financial make business

to our risks described that subject as from the filings other numerous XX-K within may uncertainties in make we with time-to-time. SEC and Forward-looking statements and are

our Participating Sath for Laurence Officer; be will Executive President. on Chief Mauney, and call Cooper, today David CFO; Dr. Shukla, Ziopharm Dr.

our Following question and open time, and that you. to one have management the the to the you free we follow-up kindly queue. commentary as of feel In Q&A. team, then a needed interest from return for request call will please Thank we

call the afternoon, to And started, I'll to get turn Dr. Good Cooper. over Laurence.

Laurence Cooper

good speak are everyone. new Ziopharm. Thanks, with Chris to welcome and have of to to who you afternoon you We're we the opportunity pleased those today. And

oral to solid in solid plan treat build By way tumors. our XXXX alone be Ziopharm of patients introduction, believe stands to the able upon in dramatic we offer forward We treatments took tumors. to vision steps to the with

upon that clinical technologies advanced based multiple We have and been innovative data. widely preclinical have convincing published

and our to X each of have on partners. with X INDs them Phase clinical and have class world alignment We execute across programs,

by solid tenure. to-date is treasury, addressing strongest after we With possible in million $XXX our now largest position under going tumors. my Ziopharm approximately in oncology markets its Finally, are the fundamental

size our highlight we the on We've been this to will execute accelerate and could gives since ability focus and successfully accomplished It sheet independence the us and Our few. on great forced scale our corporate to period, I tumors. towards time a months a deal during balance has XX solid truly vision. needed just

In addition all for property have intellectual contracts have of the cooperation multiple programs, critical we Anderson TCR-T, developments trials Street licensed in with having outreach. our to R&Ds we expanded and Wall secured our MD business extending into in have and we

assets. a much of spent understanding third each with of to gain proposition of for also our parties We core XXXX well-known deeper long-term valuation working the

and to our that We to develop T-cell anticipated are accelerating beyond. we are using for manufacturer feedback, our blueprint need information products. ability competitive XXXX Based and on analysis,

requirement upcoming commercial to or to starts plans finishes control trials it’d manufacturing. commercial offer be This whether clinical with to true viability term is for path and our longer our therapy. Our a

Since infrastructure for T-cell accelerating produce XXXX, are been we've investing these products to in ourselves, in Texas. efforts talent Houston, and and

from spaces have two additional and next MD Anderson open months. Center facilities Cancer leased in laboratory we’ll We the

include were and on multiple had We January, manufacturing details and meetings will more plans in GMP we have the JP ATR this expanding At work buy-side, with share to pharma. we which this TCR-T, up scaling already our execute year. begun for sell-side Morgan for manufacturing, about large

we going we to oncology have T-cell It are for advantage unique is collectively the five is theme that dominant competitive tumors areas readily believe solid of apparent us. after and XXXX,

T-cell cells. and we're to cancer attack First, infusing kill

tumor. eliminate As kilograms the proven a of ability reminder, to administration has of a T-cell

target we're which TCRs and their Second, in are types tumors multiple present using new of are heel. antigens, to solid Achilles'

to beauty which harness system of the have solid sleeping Fourth, manufacturing non-viral the from recycle multitudes scale patients engaging use different to we immune cytokines control address needed fifth, And to from staying on to the T-cells of types modifying response. achieve tumors. function we the and genetically so eliminate plasmids based the are we killing blood, power Third, peripheral tumor. with DNA

are upside year. executing data, plan as our with throughout base. in public we a we strong as gain financial the clinical right the on have Especially, right and potential with We assets right and company now place tremendous a the

President, Laying will out QX turning Shukla, the recent programs; the this the agenda call for prepared as conclude our as then discuss operator remarks call to CFO, questions. with our XXXX the timelines returns; updated of and our for financings, Sath then well for core David our Mauney, each over the before financial will

IND an therefore, and the our We and update trial recognize TCR-T how With on patients information the X this to update me Steve based to we of remain come first the with recent where we why remains provide the by most guidance several on trial let status game-changing and wanted Rosenberg NCI about is more that Ziopharm. Phase provide program. study. relative Dr. That's granular to dosing on delays the first in The on feedback start relieve past with for this our this concern on that, study an trials stand starting. the at excited I’ll NCI

we several puts team. enrolled. includes research the for group production an any place In This recent process. great NCI learned have the that of is trial deal there months, for After first NCI NCI steps and the is before are transfer IND to a cleared, in about patient the manufacturing

identified been diligently our patient near Drew Rosenberg Dr. and sleeping his manufacturing had produce Denninger working enrollment, have we process and used TCR-T. with As to to Dr. the team, group improvements and modified

are I'm helped Their exactly report TCR-T happy our to also of upon the be are a Anderson. that the in interim, at MD to Anderson. as the neo-antigens most to is will that have the program appropriate patients on first This then will Rosenberg system. clinical the as data the which considered at year. enroll patients NCI, they TCRs when NCI the which build our to only and undertaken sleeping beauty these made. process TCR towards through come I These the proven first first have continue final the input resected what the to going moves Dr. reviewed ready engineering this and estimate candidates the they tumors The very identified production the NCI patient. significantly be for new completed study. want our Based engine who learnings their we procurement benefit is of In but also control own moving recent to of the half of partner program runs, ingenuity. with the Ziopharm this do efforts the not T-cells, of use de-risk evaluated from NCI, treat as study in will trial the we

we're We with and eager are to plans enrollment, first to for process share the enrolled. NCI of news updates the and patient confident the

I've mentioned our January’s under program control. webcast in we the bring are update, TCR-T implementing also plans to

important new One research which XXth growing program, MD our on announcement for home encompass team an of October our development milestones year's and and provides TCR-T with agreement last of was interest Houston. and our the expanded Anderson to in

MD target with TCR’s Ziopharm on differentiator it's two relationship execute existing solid infusing it neo-antigens One us for approaches enables library in to uses as The competitive to led a significant in tumors. TCR-T occurring Anderson hotspots. a

produce work packs at the methodology IMD the chance system and many treat tumors. NCI is TCR-T target the on These Both two neo-antigens. provide the use developed types based beauty the personalized patients under of to using approaches NCI. to the of other to us sleeping The best solid same

to Indeed, targeting of At program. patient MD Anderson, set hotspots. patients access our in we flow library neo-antigens TCR-T TCRs the enrollment solid TCRs begin variety hotspot licensed can to with anticipate we of the will of to accelerate expansion a NCIs and trial. our and already tissues significant enroll to enough the patients tumors is and the The of

We roadmap, and FDA continue currently regulatory on targeting tumors. our to in work approaches engaged on are with neo-antigens solid two our

open an with believe provides for We the and these head IND with NCI a that us Phase template II having a start discussions. already

will protocols we the strong patients have success tremendous progress. we've the a value TCR-T opportunity tremendous of is a everything seen discussions We to-date, chance as updates provide those program and The believe for we creation. timing With company. in and regarding

we positive orphan program, controlled Next, will designation have program. us fast we track made on clinical IL-XX in I received granting Europe, drug In IL-XX designation. received an XXXX, feedback our in considerable touch FDA and and our progress

have XX patients highest We with XX patients to combination completed the study in included studies, levels. dosing enrollment our at glioblastoma or expansion the two X Phase GBM with which monotherapy patients an and dose treated the study escalation additional XX Opdivo, recurrent in

come online enrollments last GBM sites five third the X Regeneron's for now study should in of XXXX, Libtayo, seven call, study that half recurrent of recurrent in in combination sites a than over received dose with XXXX. Phase at effect. desired quarter achieved alone. additional GBM anti-tumor clinical the have first quarterly Beginning In an have our been those commenced and with veledimex, XX since we with complete XX steriods, Since with of quarters enrolled patients. XX immune-mediated of help than XXXX enrolling three we patients patients which more total, milligram IL-XX low treated believe the More dosing patients XX of

patients immune The indications, encouraging inform on results outside can we IL-XX potentially the in GBM. GBM, patient recurrent or meaningfully it our will of expected later then clinical program the decision from if and help believe stage combination many and these in in with data studies extend recurrent alone improve checkpoint to-date inhibitors. additional have either other outcomes in could cancer that We this effective seen be

or presented monotherapy journal can during XXXX, were and found at main Neuro-Oncology Web of August. ASCO published Results Phase in to in SNO, also these the the our Medicine published Translational were X presentations on site. from or from Science Links Society in November. data June these studies at be Considerable the last including trial

presentation months regression ago provided glioblastoma first Our of of on a imaging. evidence for team's the time at SNO based few

We recurrent median demonstrating survival receiving presented dose overall patients in data, disease low month steroids. unifotal XX also confirmatory with

increasing SNO Ziopharm that note on are interest at based JP five also encouraged in the community the investment at data, to and pleased among potential Morgan. our are with partners we the team top and this meetings these consistent award by received the is This enthusiasm program. We

to continue the with in abstracts the medical first enrolled anticipate major in monitor providing meetings patients half additional for this updates and studies We at year. potential of of submission these multiple the

announced cleared at in XXXX we FDA Anderson. trial that program. I MD will our to investigator October clinical the conducted another with Phase for had X conclude update an initiated be important an IND CAR-T on milestone, In

criteria. leukemias process, donor soon the As as we release personalized marrow lymphomas we can evaluate the Under study transplantation. expressing will after the derived in RPM stated, CAR-T this through but rapid with CDXX verification at who bone day and as CAR-T transfer, including RPM allogeneic after patients created patients previously or infusion relapsed have those have manufacturing gene needs

call, working quarterly last we of Anderson to started trial get said our was the our with During the team by MD end hard XXXX.

the the investigator As to site underway principal our half year, look Indeed a sharing rounded regulatory patient trial, our in product MD initiation of we the the the pleased And qualification coming with were the as well of to forward first by transition first initiation visit or the is we planned I'm this step you you the Anderson are for some gone in study things And important the near-term and weeks. batches their referred for Final is to an delays facility. manufacturing for milestone this GMP tell have year. to SIV experienced this views being is technology as company. But reminder, identified study. since. required as out with

CDXX of and autologous with infusion. years infused malignancies, XX% outcomes all marrow patients demonstrated data regarding sleeping two use Four overall after term bone the XX% reprogram was generation progression are in Blood recent of system T-cells. of on encoring month of free infusion refractory received whom specific mention had encouraging sustained technology. persistence transplantation. the this a respectively. sleeping of to B-cell beauty items or describe Five-year relapsed journal after our This long lymphoid and beauty many published survival modified outcome of based CAR-T CAR-T CAR-T patients we There survival to long-term additional Last prior

the Last data the reduce new the show from annual validating membrane data anti-tumor preclinical effects. and rapid system complexity meeting exhibited on express our T-cell team manufacturing therapies. sleeping bound ASH with December, TCR. These T-cells plasmids personalized to to our These presented beauty cost modified that genetically build IL-XX approach of with using XXXX TCR results at DNA

Things technology BioCell. and have in They on hospital we are our the uptake RPM scientists well runs is venture currently Taiwanese the the conducting an The progress Greater Finally, large first and our to of staffed Eden as China. with joint the at tech is commenced for complete, a trial GMP discussions Taipei. in continue transfer the also to FDA largely facility manufacturing colleagues start process. the equipped test with expect RPM

BioCell the situation corona CDXX advise Taiwan. to-date this the Eden's we virus It not partners Eden to significant filed with new for work IND is Our while will are us prevented year. be that will trial ability noting at worth to experiencing in restrictions continue And monitored, not RPM the be delays. have China autologous the in CAR-T travel

In data the past And breadth Ziopharm. of to programs, Shukla. RPM and now, for will progress T. potential funds These TCR-T, have controlled the our throughout significant hand we CFO, creating future; programs technology, unique call and have summary, this significant the over dispose opportunities we I for appears value provide expect CAR months, the well assembled the insight to and XX our to upside and Sath in deeper year clinical made all on people and into IL-XX

Sath Shukla

and everyone. Laurence, Thanks afternoon, good

that Let in keep the words for capitalized few comparison with therapy is our tumors. all cell saying financing patients and recent competitors develop essential the It we solid gene by to to well our company me begin space. treatment to vision about in a achieve efforts

the capital avoid at disclosed need the political it We risk have first risky. which do XXXX, the at a to carefully in that runway for We time reaching quarter to opinion that but this expected we audit months a raise the the As our time first this going we balances company be considered exposing meant while end the would was evaluated into year, to market third of to to came provided several that XXXX, catalyst timing imprudent. of capital hoping concern half markets and right conclusion XXXX. exact of and we and cash of the

could late executing of on starting risk engaging were December, many waited additional million. financing available too securing and the we secure ATM if $XX that capital We biotechs post and for fatigue began given approximately financing. limited XXXX, Furthermore, in funding some our deal in early in therefore XXXX sheet fortifying potential to first, balance long substantial

was top achieve we event balance pivotal the The tier management quickly, also achieved successful of a in and proceeds the accelerate investors, following de-risked prospects ATM shared traditional tow company. where years financing However, using to company's biotech the to JPM This addition turned for enable the future. our and for will us market and in the sheet, the anytime many engaged important multiple off a at and financing. current in goals next prices near necessity conditions preclude ATM the now

see of this and We gene investment, long-term. support of provide broadening accelerate personal clinical factor area both almost manufacturing. cell the campus controlled infrastructure, in initiatives medium state a serves out use control substantial support toward next, for been to for we new MD more program potential therapy capital our Houston advance great manufacturing the and Ziopharm studies down Anderson, these now whom which and the and new the limiting for for to library as TCR of of manufacturing of of the potentially take build can TCR personnel many compared expansion drill of think many will peers, TCR we to path accelerate other hotspot bit our our serve to the which The fiscal on and to daily TCR with our specialists a concretely program advance our as recruitment indications; can; foundation control IL-XX first, value alone related news our will proceeds, also and have facility the we and, new commercial personnel purposes program; our second, of for and we trial; later

to the for results fourth specific financial Ziopharm XXXX. Turning of quarter

company’s and expansion programs. research controlled Phase release, news were to million development increase QX QX our both the XXXX This of in of $XX.X for noted of well the as CAR-T reflects compared as X million Libtayo, trial XXXX. the TCR As including IL-XX initiation look and combination $X.X of expenses programs, for of clinical for

$X.X key quarter reflects for the quarter This were expenses $X.X of XXXX. our compared headcount, for recruitment G&A and expanded personnel increase of to million fourth of capabilities. the XXXX million increased fourth

per million the to $XX.X shareholders we $XXX.X of $X.XX the loss diluted. share stock its the of in the quarter diluted On for for increased under Series pharma shareholders preferred of of Ziopharm basis the a pharma of Ziopharm company’s and common held income basic or million applicable or obligations from million. primarily a a $XXX XXXX, cumulative accounting the forfeiture per net in fourth and shareholders basic relinquishment applicable net and of reported resulted income Comparably XXXX partner to X fourth quarter $X.XX approximately return recorded attributable The common and all share. common by to agreement, XXXX,

expenses For R&D science. in below $XX.X million progressing G&A the in discipline ramp the $XX.X $XX.X the $XX.X the in in in XXXX, to capital spend, slightly came compared reflects R&D company's XXXX, at XXXX. the maintaining to at G&A full million, year approximately commitment focus while allocation million continued while came million on on optimal to spend, The

and business compelling We capitalize best to technologies. on possible in Ziopharm growing our position are dedicated to putting the our

payment activity, the million balance under Anderson at mid-XXXX. year funding and I conducted cash addition David to now cash of the by for million for for comments. all turn financing into now, enables infrastructure position our final will provide our over to our And call programs Incorporating us recent we to had end, in $XX MD new In company to approximately at also the a the be work agreement. $XX.X build

David Mauney

Thanks.

a new some virus Before corona I word Covid-XX. or I'll on comments business, provide on share brief our

those out of all this go by Our difficult affected to thoughts illness.

have and mitigation a business, our the illness broader begun the of may assessing currently needed. have impact spread on as plans are We identifying

they expect in As business do CDXX noted, our Greater currently confirmed disruption making Laurence and Eden at colleagues significant China. have TriArm our in and they continue that not progress program

enrollments our either have which nearing are ongoing complete clinical all we in S., drug in Further IL-XX U. available complete are or trials, completion and the of our studies. to

TCR-T appear Our by clinical the unaffected planned outbreak. trials

possible impact all. evaluating situation will virus new other of S. day Anderson to including expect the may employees’ with to NCI MD and discuss our have our as of the We the day corona we the course, activities. U. in of the this the And partners, impact be on

in that work most needed. employees allow Fortunately, if our the we systems IT place have of already from remotely

We achieved to have be our forward the future. the solid rewards if provide significant patient I things that to in achieve next many XX can any and a look And like obviously vision, to which prosperous last to strongly options months tumor. generation therapeutic goal, would is seen. we with treat reinforce

the We create which have us hard unique Laurence tremendous opportunity market worked billion and fast for attributes covered has for has and commercial rights to Ziopharm, markets. is today as multiple Ziopharm to dollar

of continued engaged have each and increasing potential the of Laurence data in as We're and assets. dialogues for we propositions mentioned, our course multiple partners value on timing with

we assets. financings, and discussions considering move we foundational technology can in now build are recent beyond where upon additional the our With also IP our to efforts have outlook in to licensing

internally and review these assets. parties engaged have development and We expanded business term capacity on plans and we each longer third of for to valuation advice our have

position, over three year. collaborative significant additional will data therapies. this human of both flexibility our pursuing an in the for have licensing our providing existing to and hand us expect programs transactions This technologies us enviable for across in We in course put

over capabilities. trend And people hand, tier C-Suite. more building. expect the to at in including the the XX we on and the already people year, comments resumes few excellent with year are even top with A this we landing last expect continue We hired organization in

up We going scheduled efforts our have are meetings especially Relations activated we calls, our monthly shareholders and expanding face-to-face outreach and Investor major and increase building forward. have our on to plans will with

of firm new new rolling, Especially trials new rebranding. and should look full in completely were our the are We've October are that we all for ticker. corporate different a company of engaged in and a and a process XXXX name as Coast we get feel, a a than include and stock we West

get look expect market roll to We to of rebranding updating half as on and effort this in year, this out second we process more closer. timing the specific forward and the

And thing It impact been effective scalable, years cost provide patients, of with not hasn't cancer say movie continued for us. true have have there now out gives immunotherapy the of many but even the was always to fortitude, just uncanny Laurence's an certainty, I an the for over the script for rational, see questions. that predictions before them seeing the vision all them. call some his And the of can one is the knack you I with largest your ago we easy commitment written. can backing, training come on Thank all operator If to markets a and is for play to that, turn support.

Operator

[Operator and Instructions] First Company. from with of the question I-Eh line Jen Laidlaw comes

Your open. now line is

I-Eh Jen

for you clinical Maybe so And quite study adjustment will more have is thanks the the wait start complete homogenized taking protocol, a remarkable Good the to one an protocols, here, TCR-T of quick two Are in you that? progress and over on afternoon. patient development. modification MD terms Anderson MD before the enroll in or on you going altogether. additional for Anderson first for NCI and to have of questions guys the congrats the questions protocol their work sort the that’s

Laurence Cooper

start MD NCI you the alongside to is that can clinical a NCI. value, the forward. only Anderson, with but going So great today us anticipate has those program to not trials The

clinical trials. Dr. and see You I his Anderson Rosenberg and iteration by continued could those and into CRADA group our expect learnings under MD back our will think

it company, develop with we a to and for put solid his the relationship essentially we're but enjoy want So leading group all Steve foundry we as tumors. the to together, drugs commercial

and about will vision MD Anderson that we that so to And say going at we'll have have execute more on then forward. to

I-Eh Jen

the anticipate on perspective, guess that expenditure Anderson you on I we could the TCR-T, that we work once MD to than maybe R&D more follow-up bit substantially a start then model? revenue from otherwise will cost increase And little

Laurence Cooper

runways there model put that, look Yes, be in R&D if because we back and R&D to so and of ramp obviously expected, and company. we And the cash, year ramp actually But I-Eh. closed this are OpEx the get and review sort right try an obviously, in on just that how back cash we’ll next us we for much year expenditure anticipating will are of XXXX, yes, we'll into the year in we our at you this XXXX. can a middle a also now into of taking on you sure, sort and then we going

So certainly, more. we the will more therefore expectation is spend we execute that and will

Operator

from Our Lake Thomas from Flaten question next Street Capital. comes

Thomas Flaten

the so in those on earlier understand another? around one you're just some IND alongside specific discussions clearances things like still respect Anderson NCI, provide on MD that follow-up alongside with with how cetera, and to will discussions, that. things study we TCR submissions running Could the you To et given FDA granularity question run protocols more those

Laurence Cooper

in I about of that at playbook it to come rest way and with and regulators, the then the Those we has commercial they established Steve and the update been adapted will take our in our you Anderson. We underway are terms Rosenberg. And plans think is, to market fuller now detail. the by needs on I will facing discussions soon. MD think IND, own the playbook

Thomas Flaten

data programs I'm on we you second across kind then in Could the together queue, might broad data of three with and half jump And I'll having with expect see? of back types what having XXXX. in guidance? trouble then a all just the to the comment tied little that, seeing come of timeline for to for bit into respect kind

Laurence Cooper

slide a actually We've the deck. got on that's

X positioning we we’re personalized programs rapid the the a Phase moment, we’ll the first have the have we'll have in of IL-XX really announcement X Phase the the readout to company around And completion expanded readout in is enrollment manufacturer X the a of NCI Phase our for We'll controlled of have that’s for cohort. so We'll as trial this We'll enrollment data controlled with those data with and our monotherapy XXXX CAR-T. a Opdivo. in from look data end dosing X. trial in you with IL-XX at at book Libtayo. a readout Phase So initial at way just the half that combination combination controlled as IL-XX have

half get half we’ll the those then quarter you we of essentially look so, into as the into the will this can year. So then activities five this deeper company that And or second move timeline be year. first next of the that in so for

a pretty this for half. first jus significant that's So package

Thomas Flaten

in actually going if of in Just number have you're to so half so can to respect Do Rosenberg first follow-up, NCI. a dosing that from of cadence you be the with get sense data at enrollment you a patients, out XXXX?

Laurence Cooper

having program. impetus the of and same Dr. INDs rapidity our MD with and Houston But an the regularly the around for our Rosenberg, field to So down put quite with that to a moving Anderson. steward be us expect updates, them technology own said do really timeline been of the by frankly with to and our that's governed excellent lot Steve's and technology respect that, to important and out is the I public under

Operator

comes RK from question next of Wainwright. H.C. Our

Swayampakula Ramakanth

Just as on the on you’re process program, the more NCI itself. learning the about

So after do else to to these Is runs get they they manufacturing going? get anything study need for that before clinical material there successful started. NCI runs the

Laurence Cooper

be IND. then can a the then once added Steve obviously, go, my the the comments around of was are learning heard the is is And then part treated. that's patients you’ve top the So governed in on how to IND, then manufacturing, ready queue under important essentially that

I only then not therapies of that that there's think, transition TCR essentially to they story the be, patients So clinical Steve the where but important governs into that to come going box, need I that checked have an clinical essentially as when receive that manufacturing queue the think part trial. essentially he’s need the solutions, and patients essentially off

Swayampakula Ramakanth

which ones Outside you are would the target would going controlled the and costs issue, you IL-XX likely of GBM, after? on what tumors be if think no And are program. is

Laurence Cooper

So that's whole checkpoint we teaches tumor tumors for data important, hot, failed and that can clinical IL-XX really inhibitors. us, turn that especially in the think for us our have

closely we types tumors. benefit other frankly, those those affected match influx tumors set So there's there, of deserts, from quite the of up be actually a In and out immunological at an checkpoint are tumors ones in T-cells, inhibitors. words, which RK, that and of don't those often looking immune from to they once can

Swayampakula Ramakanth

end first half. the Is date then the And is it that the regarding other… half expected any the first during pretty into be ASCO, till of could question wait the or last much

Laurence Cooper

be could It throughout divergence We a of half. see continued data first this anytime.

Operator

you. Thank

Our next Birchenough comes from with question Wells Jim Fargo.

is line open. now Your

Unidentified Analyst

on congratulations Jim -- for great this this the company. afternoon, be to this year Nick is on like It’s going for seems

So excited I'm the progress. sure about all you're very

of that the algorithms in similar. NCI two like also very approach be trial, identify Just approach the technologies difference will terms the trials trials. hotspots the will the It be and antigen Is case? differential, new in the and here the terms to of outside your hotspot seems of between the used

Laurence Cooper

broad frankly patients, solution Both Yes, Ziopharm the therapy. very personalized TCR-T that's I NCI for most and a good tumors. actually quite pursuing really think with point, solid the Nick. That's starting a will be

as faster, you're its partner with but treat mutated And the a Ziopharm though, do because trial. patients to the that’s developing antigen. you will patients MD to the the be a screening at of hotspot Anderson know addition, for In subset much way

Unidentified Analyst

you to will certain you -- be, a that will trail, to be or well, from TCR it have KRAS, look an example? that essentially already at for trial a on be made execute comment subset initially you enough library in think I position Will all-comer let's trial. a the you And

Laurence Cooper

Nick. We're question, basically FDA the those then we'll type right we in designs. to want the design on back and there's kinds you. dialog from And exactly of trial feedback that, of trial that's that about get No,

Unidentified Analyst

cash And then the and you to in queue, last and have so one I'll the referred you form me through back of ‘XX. middle now IL-XX,

your Because to midyear assuming data I forward have of for by program. preferred think the beginning way partnership. of terms point to you 'XX? that past, think going through You're trials are was in in the IL-XX this middle additional I at one recall critical a with What

Laurence Cooper

study anti-tumor We've got trial really come data, as evidence are I survival, and now. Opdivo, mean, got in, scan. month seen MRI through of effects we've so significant we've based pretty the expansion No, long-term Nick. Phase the XX think especially with data on clear or I study X the reassuring

patients have of serially T-cells. and biopsied We these shown influx

data to going was I what a think these I since essentially sense options Ziopharm at for look the that company's are really correct. at that the now and we're and these So was But coming partner. see through the for are work year think means essentially were done many data makes company. those out lot potential there, a there in put a There comments of for time look the the best

Unidentified Analyst

additional have for to 'XX? that you just assigns additional clarify, do trials money -- So 'XX, starting in

Laurence Cooper

I'll Sath Sure, to it turn over here.

Sath Shukla

our So this runway say not is does I conservatively think what assume that push partnership point. can I any and at cash

runway. when built our we of we conservatively, in progress have to any the and do could partnership that But to which layout with and assumed for to purposes we comes the analyses. the whatever So company data of in funding Obviously, explore that any program potentially in indications, and rollout and for want other GBM the not we our from today planning cash change. whether number funding that partnerships and you decide

Operator

you. Thank

I-Eh up question a Our is final Jen. follow from

Your line open. is now

I-Eh Jen

or methods? you release Are some at other TCR-T MD Anderson when you the to sort guys the going pace announce in press of saw on the study the

Laurence Cooper

just the when starts, TCR-T to NCI. will at So clarify, trial the announce we enrolls

guide MD own commercial Anderson. also the activities for on our at our will market plan We

I-Eh Jen

study, related record half maybe to anticipate combo we Should here, of this terms of rate datasets? time or is just this survival which others, or data one Opdivo year? intend more on And to anything you mainly duration of in the that focused the question just the endpoint that which the such free other is relevant progression simply and as, so study response the

Laurence Cooper

in will survival, antigen. often move be do to is biopsy color and is work by that’d through addition, response with -- the to able products they that company show that's or try I -- because to What the through for allow as centers, the instance the tries data, as add well data, But to immune do those whether what we forward. potential academic additional because FDA, which benchmark, we’re

first So this I last is at as we the that of of for out company the back will this poster And put can guide, put anticipate type half that together template apprise tree year. our the of the look a be you essentially activity. keeping package is SNO November the for way

I-Eh Jen

very progress the again, And so very, far. on That’s congrats helpful. great. Okay,

Laurence Cooper

for day. the a that everybody and much good very you concludes think have I And Thank questions. call Okay.

Operator

for Ladies you and and program today's participation conclude This gentlemen, your you disconnect. on thank now does may conference. your

Alaunos Therapeutics (TCRT) 2 Mar 202019 Q4 Earnings call transcript